Send me a link:

*Only U.S. numbers are accepted. Text messaging rates may apply.

 Dow Down0.08% Nasdaq Down0.83%

BIND Therapeutics, Inc. (BIND)

-NasdaqGS
10.09 Down 0.42(4.00%) 4:00PM EDT
Get the big picture on all your investments.
ProfileGet Profile for:
BIND Therapeutics, Inc.
325 Vassar Street
Cambridge, MA 02139
United States - Map
Phone: 617-491-3400
Website: http://bindtherapeutics.com

Details 
Index Membership:N/A
Sector:Healthcare
Industry:Biotechnology
Full Time Employees:59

Business Summary 

BIND Therapeutics, Inc., a clinical-stage nanomedicine platform company, develops various targeted and programmable therapeutics. It is developing Accurins that are designed with specified physical and chemical characteristics to target specific cells or tissues and concentrate a therapeutic payload at the site of disease to enhance efficacy while minimizing adverse effects on healthy tissues. The company’s lead Accurin drug candidate includes BIND-014, a prostate-specific membrane antigen targeted Accurin that contains docetaxel and is in Phase 2 clinical trials for non-small cell lung cancer and metastatic castrate-resistant prostate cancer. It has collaboration agreements to develop Accurins based on therapeutic payloads from their product pipelines with Amgen, Inc.; Pfizer Inc.; and AstraZeneca AB. The company was formerly known as BIND Biosciences, Inc. and changed its name to BIND Therapeutics, Inc. in April 2013. BIND Therapeutics, Inc. was founded in 2006 and is headquartered in Cambridge, Massachusetts.

Key Statistics


Company Websites 
Home Page
Search Yahoo! for:
More on BIND Therapeutics, Inc.

Key Executives 
 PayExercised
Mr. Scott L. Minick , 62
Chief Exec. Officer, Pres and Director
508.00K0.00
Dr. Robert S. Langer Jr., Ph.D., Sc.D, 65
Co-Founder, Chairman of Scientific Advisory Board, Consultant, Director and Member of Nominating & Corp. Governance Committee
125.00KN/A
Dr. Jeff Hrkach Ph.D., 48
Chief Technology Officer
352.00K0.00
Dr. Gregory I. Berk M.D., 56
Advisor
385.00K0.00
Mr. Andrew Hirsch , 43
Chief Financial Officer, Chief Operating Officer, Principal Accounting Officer and Sec.
N/AN/A
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders